<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634164</url>
  </required_header>
  <id_info>
    <org_study_id>17757</org_study_id>
    <nct_id>NCT02634164</nct_id>
  </id_info>
  <brief_title>The Effects of Leucine and Isoleucine on Glucose Metabolism</brief_title>
  <acronym>AA+GLU</acronym>
  <official_title>The Effects of Leucine and Isoleucine on Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Woman's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Woman's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is classified as an impairment of the body's ability to control blood glucose
      levels. Uncontrolled hyperglycemia can give rise to macrovascular (i.e., heart disease and
      stroke) and microvasculature damage such as retinopathy, nephropathy and neuropathy. These
      comorbidities may definitively reduce quality of life.

      Hypotheses to be tested:

        1. The ingestion of amino acids L-Isoleucine and L-Leucine at a therapeutic dose prior to a
           glucose load will concurrently and independently improve glucose tolerance.

        2. The ingestion of L-Isoleucine and L-Leucine separately or together will have a minimal
           effect on incretin responses of Glucagon-like peptide-1 and Glucose-dependent
           insulinotropic peptide (GLP-1, GIP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims and Hypothesis Diabetes is classified as an impairment of the body's ability to
      control blood glucose levels. Uncontrolled hyperglycemia can give rise to macrovascular
      (i.e., heart disease and stroke) and microvasculature damage such as retinopathy, nephropathy
      and neuropathy. These comorbidities may definitively reduce quality of life.

      Hypotheses to be tested:

        1. The ingestion of amino acids L-Isoleucine and L-Leucine at a therapeutic dose prior to a
           glucose load will concurrently and independently improve glucose tolerance.

        2. The ingestion of L-Isoleucine and L-Leucine separately or together will have a minimal
           effect on incretin responses (GLP-1, GIP).

      Specific Aims:

        1. Specific Aim I will test the hypothesis that the ingestion of amino acids L-Isoleucine
           and L-Leucine at a therapeutic dose prior to a glucose load will concurrently and
           independently improve glucose tolerance.

        2. Specific Aim II will test the hypothesis that the ingestion of L-Isoleucine and
           L-Leucine will have a minimal effect on incretin responses in conjunction with prior
           research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma glucose (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma insulin (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma GIP (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood Collections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma GLP-1 (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood collections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucagon (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma c-peptide (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood Collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma L-Leucine (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood Collections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma L-Isoleucine (0-150 minutes)</measure>
    <time_frame>baseline (0), 2, 4, 6, 8, 10, 30, 32, 34, 36, 38, 40, 60, 90, 120, 150 minutes</time_frame>
    <description>Blood Collections</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Treatment with Oral Glucose Tolerance Test:
Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leucine Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control Treatment with Oral Glucose Tolerance Test:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoleucine Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoleucine Combined with Oral Glucose Tolerance Test:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leucine and Isoleucine Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Leucine Supplement</intervention_name>
    <description>For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution</description>
    <arm_group_label>Leucine Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoleucine Supplement</intervention_name>
    <description>For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.</description>
    <arm_group_label>Isoleucine Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Leucine Supplement combined with Isoleucine Supplement</intervention_name>
    <description>For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.</description>
    <arm_group_label>Leucine and Isoleucine Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age range of 20 to 40 years of age

          2. (sedentary lifestyle) Participants whom exercise less than the American College of
             Sports Medicine recommendation of weekly physical activity levels or are completely
             sedentary may be admitted into the study

          3. Apparently healthy

          4. Currently not using supplemental branch chain amino acids (BCAA) or whey protein

          5. Non-smoking

        Exclusion Criteria:

          1. Chronic or acute health problems

          2. Smoker

          3. Currently using supplemental BCAA or whey protein -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vic Ben-Ezra, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Texas Woman's University Kinesiology Department</affiliation>
  </overall_official>
  <reference>
    <citation>Yoshizawa F. New therapeutic strategy for amino acid medicine: notable functions of branched chain amino acids as biological regulators. J Pharmacol Sci. 2012;118(2):149-55. Epub 2012 Jan 27. Review.</citation>
    <PMID>22293293</PMID>
  </reference>
  <results_reference>
    <citation>Nuttall FQ, Schweim KJ, Gannon MC. Effect of orally administered phenylalanine with and without glucose on insulin, glucagon and glucose concentrations. Horm Metab Res. 2006 Aug;38(8):518-23.</citation>
    <PMID>16941278</PMID>
  </results_reference>
  <results_reference>
    <citation>Gannon MC, Nuttall FQ. Amino acid ingestion and glucose metabolism--a review. IUBMB Life. 2010 Sep;62(9):660-8. doi: 10.1002/iub.375. Review.</citation>
    <PMID>20882645</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalogeropoulou D, Lafave L, Schweim K, Gannon MC, Nuttall FQ. Leucine, when ingested with glucose, synergistically stimulates insulin secretion and lowers blood glucose. Metabolism. 2008 Dec;57(12):1747-52. doi: 10.1016/j.metabol.2008.09.001.</citation>
    <PMID>19013300</PMID>
  </results_reference>
  <results_reference>
    <citation>Nilsson M, Holst JJ, Bj√∂rck IM. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Am J Clin Nutr. 2007 Apr;85(4):996-1004.</citation>
    <PMID>17413098</PMID>
  </results_reference>
  <results_reference>
    <citation>Petersen BL, Ward LS, Bastian ED, Jenkins AL, Campbell J, Vuksan V. A whey protein supplement decreases post-prandial glycemia. Nutr J. 2009 Oct 16;8:47. doi: 10.1186/1475-2891-8-47.</citation>
    <PMID>19835582</PMID>
  </results_reference>
  <results_reference>
    <citation>Doi M, Yamaoka I, Fukunaga T, Nakayama M. Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes. Biochem Biophys Res Commun. 2003 Dec 26;312(4):1111-7.</citation>
    <PMID>14651987</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1292-300. Epub 2004 Dec 9.</citation>
    <PMID>15591158</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leucine</keyword>
  <keyword>isoleucine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

